CONCLUSION: In this study, risperidone was associated with improvement in ADHD symptom severity and global functioning in carefully selected children with ADHD and prominent behavioral dysregulation. However, treatment was also associated with clinically relevant metabolic and endocrine adverse effects. These findings support selective use as a pharmacological adjunct to behavioral intervention in closely monitored patients with significant behavioral comorbidity, and do not justify routine use…
